Compare
PDS Biotechnology Corp vs Yarrow Bioscience, Inc. vs Sunshine Biopharma Inc. vs China Pharma Holdings, Inc.
| Latest fiscal year | PDS Biotechnology Corp PDSB | Yarrow Bioscience, Inc. YARW | Sunshine Biopharma Inc. SBFM | China Pharma Holdings, Inc. CPHI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $570.0K | $36.31M | $4.14M |
| Revenue growth (YoY) | n/a | +13.8% | +4.1% | -8.5% |
| Gross margin | n/a | n/a | 33.8% | -3.2% |
| Operating margin | n/a | n/m | -17.2% | -78.2% |
| Net margin | n/a | n/m | -16.5% | -76.9% |
| Net income | -$34.50M | -$26.48M | -$5.98M | -$3.19M |
| EPS (Diluted) | -$0.74 | -$0.62 | n/a | -$0.74 |
| Operating cash flow | -$27.75M | -$33.12M | -$5.33M | $148.3K |
| Free cash flow | -$27.75M | -$33.12M | -$5.51M | $88.9K |
| Cash & equivalents | $26.71M | $24.03M | n/a | $345.1K |
| Total assets | $30.49M | $30.16M | $30.08M | $31.00M |
| Total liabilities | $21.24M | $2.40M | $7.04M | $8.26M |
| Shareholders' equity | $9.25M | $27.77M | $23.04M | $22.74M |
| Return on year-end equity | -372.9% | -95.4% | -25.9% | -14.0% |
| Shares outstanding | 54.88M | 33.32M | 4.91M | 15.52M |
Revenue, most recent five fiscal years
| Fiscal year | PDS Biotechnology Corp | Yarrow Bioscience, Inc. | Sunshine Biopharma Inc. | China Pharma Holdings, Inc. |
|---|---|---|---|---|
| Latest | n/a | $570.0K Ended 2025-12-31 | $36.31M Ended 2025-12-31 | $4.14M Ended 2025-12-31 |
| 1 year earlier | n/a | $501.0K Ended 2024-12-31 | $34.87M Ended 2024-12-31 | $4.53M Ended 2024-12-31 |
| 2 years earlier | n/a | $424.0K Ended 2023-12-31 | $24.09M Ended 2023-12-31 | $7.01M Ended 2023-12-31 |
| 3 years earlier | n/a | $477.0K Ended 2022-12-31 | $4.35M Ended 2022-12-31 | $8.10M Ended 2022-12-31 |
| 4 years earlier | n/a | $931.0K Ended 2021-12-31 | $228.4K Ended 2021-12-31 | $9.64M Ended 2021-12-31 |